Your browser doesn't support javascript.
loading
Association of circulating manganese levels with Parkinson's disease: A meta-analysis.
Du, Ke; Liu, Ming-Yan; Pan, Yan-Zhu; Zhong, Xin; Wei, Min-Jie.
Afiliação
  • Du K; School of Pharmacy, Department of Pharmacology, China Medical University, Shenyang, Liaoning 110122, China.
  • Liu MY; School of Pharmacy, Department of Pharmacology, China Medical University, Shenyang, Liaoning 110122, China.
  • Pan YZ; School of Pharmacy, Department of Pharmacology, China Medical University, Shenyang, Liaoning 110122, China.
  • Zhong X; School of Pharmacy, Department of Pharmacology, China Medical University, Shenyang, Liaoning 110122, China.
  • Wei MJ; School of Pharmacy, Department of Pharmacology, China Medical University, Shenyang, Liaoning 110122, China; Liaoning Key Laboratory of Molecular Targeted Anti-tumor Drug Development and Evaluation, Shenyang, Liaoning 110122, China. Electronic address: minjie_wei@163.com.
Neurosci Lett ; 665: 92-98, 2018 02 05.
Article em En | MEDLINE | ID: mdl-29191695
ABSTRACT
Whether systemic manganese (Mn) dysfunctions in Parkinson's Disease (PD) is still under ongoing debate. The recent reported studies on the circulating Mn levels in PD showed inconsistent results. A meta-analysis study was conducted to evaluate the association of circulating Mn levels with PD, and to clarify whether Mn should be considered as a potential risk factor for PD. A systematic searching was performed based on PubMed, web of science, and China National Knowledge Infrastructure (CNKI). Finally, 22 studies were identified, involving 637 PD patients and 802 health controls (HC) individuals for serum Mn, 1258 PD patients and 1304 HC individuals for peripheral blood Mn, and 195 PD patients and 196 HC individuals for cerebrospinal fluid (CSF) Mn. Forest plots were adopted to represent the comparison of the groups by assessing standardized mean difference with random effects model. This meta-analysis revealed a significantly increased serum Mn levels in PD patients (SMD=0.78; 95% CI [0.32, 1.24]; P=0.001), and it was further confirmed when serum, plasma and whole blood studies were analyzed together (SMD=0.58; 95% CI [0.25, 0.91]; P=0.001). Instead, no significant differences of CSF Mn were observed between PD patients and HC individuals (SMD=-0.09; 95% CI [-0.47, 0.29]; P=0.644). These results supported the notion that elevated Mn level should be a potential risk factor for PD, although the high heterogeneity and methodological limitations recommended caution in the interpretations for the present findings.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Íons / Manganês Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Limite: Aged / Female / Humans / Male / Middle aged País como assunto: Asia Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Íons / Manganês Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Limite: Aged / Female / Humans / Male / Middle aged País como assunto: Asia Idioma: En Ano de publicação: 2018 Tipo de documento: Article